Project Grant R01AR084518
Award Date
9/24/24
Completion Date
7/31/29
Dollars Obligated
$926K
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to optimize the prediction of cancer-associated myositis (CAM) and determine how the emergence and elimination of cancer influence outcomes in idiopathic inflammatory myopathies (IIM). The $575,021 award, with a project period from September 1, 2024 to July 31, 2029, will...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), funded under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $488,575.00 to the University of Arizona to conduct research on myosin binding protein-C (MYBP-C) and its role in regulating skeletal muscle contraction. The research aims to systematically determine the distinct functional and structural effects of SMYBP-C, FMYBP-C, and their...
The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is for a study titled "Targeting Mitochondrial Permeability Transition to Attenuate Adverse Muscle Impact in Sepsis". The $193,188 award, effective from Sep 1, 2024 to Aug 31, 2026, will investigate the role of mitochondrial permeability transition (MPT) in skeletal muscle dysfunction...
This Project Grant award of $473,377 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, supports research to modulate the stem cell niche and improve skeletal muscle regeneration. The key objectives are to: Interrogate how muscle cells arise and develop functional characteristics from human pluripotent stem cells (hPSCs) through analysis of myogenic commitment factors and inhibition of...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, totaling $820,142, will support research into the influence of early-life physical inactivity on adult muscle quality and function. The project aims to 1) investigate the effect of early-life physical inactivity in mice on muscle quality and function in adulthood, 2) determine the impact on the...
This federal Project Grant award of $219,605.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify the role of the mechanosensitive ion channel PIEZO1 in driving synovial fibrosis and inflammation in post-traumatic osteoarthritis (PTOA). The research will characterize the bi-directional regulation between PIEZO1 mechanotransduction and...
This $439,791 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research at The University of Texas Southwestern Medical Center to investigate the molecular mechanisms underlying myoblast fusion, the process by which muscle precursor cells fuse to form mature muscle fibers. The research aims to gain a deeper understanding of the actin...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $1,727,423.00 to the University of Iowa over 5 years starting August 7, 2024. The purpose of this research is to investigate the role of the myokine FGF21 in the progression of skeletal abnormalities associated with Duchenne muscular dystrophy (DMD). The project aims to identify the...
This $662,241 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to address the gap in validated outcome measures and natural history for mitochondrial myopathy (MM). The primary objectives are to: 1) obtain longitudinal data on the MM Composite Assessment Tool (MM-COAST) and MM Function Scale to define their minimum...